Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Buy” from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus recommendation of “Buy” from the ten research firms that are currently covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $40.3750.

Several research firms have recently weighed in on ORKA. BTIG Research began coverage on shares of Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Wednesday, July 23rd. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Monday, July 21st.

Oruka Therapeutics Stock Down 4.2%

Shares of NASDAQ ORKA opened at $13.09 on Friday. The company’s 50-day simple moving average is $13.10 and its 200-day simple moving average is $11.45. Oruka Therapeutics has a 52-week low of $5.49 and a 52-week high of $52.32. The firm has a market cap of $490.09 million, a price-to-earnings ratio of -2.90 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities research analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of ORKA. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics during the fourth quarter worth about $54,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Oruka Therapeutics during the second quarter worth about $68,000. AlphaQuest LLC purchased a new stake in shares of Oruka Therapeutics in the 1st quarter valued at approximately $168,000. Intech Investment Management LLC purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $168,000. Finally, Cannon Global Investment Management LLC purchased a new stake in shares of Oruka Therapeutics in the 1st quarter valued at approximately $195,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.